LSD as an agonist and antagonist at central dopamine receptors.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D002540:Cerebral Cortex / Q000166:cytology / Q000378:metabolism*; D002746:Chlorpromazine / Q000494:pharmacology; D003342:Corpus Striatum / Q000166:cytology / Q000378:metabolism*; D003533:Cyproheptadine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism* / Q000494:pharmacology; D018492:Dopamine Antagonists; D004789:Enzyme Activation / Q000187:drug effects; D006220:Haloperidol / Q000494:pharmacology; D066298:In Vitro Techniques; D008238:Lysergic Acid Diethylamide / Q000031:analogs & derivatives / Q000494:pharmacology*; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011955:Receptors, Drug; D013268:Stimulation, Chemical; D013347:Subcellular Fractions / Q000378:metabolism
D018492:Dopamine Antagonists; D011955:Receptors, Drug; D003533:Cyproheptadine; D008238:Lysergic Acid Diethylamide; D011433:Propranolol; D000262:Adenylyl Cyclases; D006220:Haloperidol; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine